Trial Profile

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jul 2025 According to a Sernova media release, tegoprubart will be used in place of tacrolimus in the upcoming Cohort C.
09 Jul 2025 According to a Sernova media release, the company announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc.to evaluate Eledon's immunosuppressive agent tegoprubart (AT-1501) in Sernova's ongoing Phase 1/2 clinical trial
14 May 2025 According to a Sernova Corp media release, Interim data from 12 patients with transplanted human donor islet cells in Cohort A and ongoing Cohort B show patients achieving insulin independence, the study is on track to meet its primary and secondary endpoints, and the confirmatory Cohort C is expected to initiate in H2 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com